Table 1 Demographic and clinical characteristics (Data are n (%) or mean (SD)).
Risperidone | Olanzapine | Quetiapine | Aripiprazole | Ziprasidone | Perphenazine | Haloperidol | F/χ2 | P | |
|---|---|---|---|---|---|---|---|---|---|
n = 354 | n = 356 | n = 333 | n = 340 | n = 339 | n = 170 | n = 148 | |||
Age (years) | 30.85 (7.95) | 30.23 (7.90) | 30.89 (7.76) | 31.31 (7.66) | 30.48 (7.86) | 32.07 (7.83) | 33.47 (7.46) | 3.926 | 0.001 |
Sex | 15.493 | 0.017 | |||||||
Male | 212 (59.9%) | 183 (51.4%) | 155 (46.5%) | 168 (49.4%) | 173 (51.0%) | 81 (47.6) | 71 (48.0%) | ||
Female | 142 (40.1%) | 173 (48.6%) | 178 (53.5%) | 172 (50.6%) | 166 (49.0%) | 89 (52.4%) | 77 (52.0%) | ||
First episode | 102 (28.8%) | 95 (26.7%) | 82 (24.6%) | 96 (28.2%) | 90 (26.5%) | 39 (22.9%) | 33 (22.3%) | 4.541 | 0.604 |
CHL-equivalent dose at Endpoint (mg/day) | 270.68 (103.85) | 506.88 (205.50) | 442.57 (165.99) | 429.41 (249.52) | 387.83 (200.44) | 253.59 (132.67) | 503.97 (274.11) | 71.501 | <0.001 |
Course of schizophrenia (month) | 75.48 (68.14) | 78.38 (70.76) | 83.09 (73.57) | 76.86 (68.56) | 73.03 (67.29) | 90.14 (76.82) | 89.61 (68.76) | 2.070 | 0.054 |
Baseline QTc (ms) | 405.24 (25.92) | 403.71 (23.55) | 406.63 (27.51) | 405.11 (25.12) | 404.07 (25.09) | 405.82 (25.91) | 404.96 (27.93) | 0.482 | 0.822 |
